Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Retagliptin (SP2086) + Metformin in T2DM
NCT01969318Phase 2Completed
- Sponsor
- Hengrui
- Start
- Mar 2012
- Primary completion
- Aug 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of retagliptin in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by Hengrui. Primary endpoint: Change From Baseline in HbA1c (Hemoglobin A1C) at 12 weeks. Started Mar 2012; status: completed.
02
Drugs
retagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT01969318.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01969318.